Drug intelligence / Profile preview

EDDC-2214

Development stage: Unknown
Lead developer: Everest Medicines
Modality: Modified Peptides → Peptides, Small Molecules
Administration: Oral

Overview

EDDC-2214 is an oral small molecule peptidomimetic that acts as a potent inhibitor of the SARS-CoV-2 3-chymotrypsin-like (3CL) protease. Developed initially by the Experimental Drug Development Centre (EDDC) in Singapore and later licensed to Everest Medicines, the drug is designed as an antiviral therapy for COVID-19. It has demonstrated broad-spectrum activity against various SARS-CoV-2 variants and other coronaviruses, such as MERS-CoV, in preclinical studies. The compound is currently in Phase 1 clinical development.

Targets

Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on EDDC-2214.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDDC-2214.

Explore the full profile